Zenas BioPharma, Inc. (ZBIO)

US — Healthcare Sector
Peers:

Automate Your Wheel Strategy on ZBIO

With Tiblio's Option Bot, you can configure your own wheel strategy including ZBIO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ZBIO
  • Rev/Share 0.3588
  • Book/Share 6.8017
  • PB 2.4714
  • Debt/Equity 0.0043
  • CurrentRatio 6.4684
  • ROIC -0.6097

 

  • MktCap 703232616.0
  • FreeCF/Share -3.2954
  • PFCF -5.1051
  • PE -4.3118
  • Debt/Assets 0.0037
  • DivYield 0
  • ROE -0.9767

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 4
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation ZBIO Wedbush -- Outperform -- $35 March 20, 2025
Initiation ZBIO Wolfe Research -- Outperform -- $19 Feb. 4, 2025
Initiation ZBIO H.C. Wainwright -- Buy -- $30 Dec. 16, 2024
Initiation ZBIO Morgan Stanley -- Overweight -- $40 Oct. 8, 2024
Initiation ZBIO Jefferies -- Buy -- $35 Oct. 8, 2024
Initiation ZBIO Guggenheim -- Buy -- $45 Oct. 8, 2024
Initiation ZBIO Citigroup -- Buy -- $27 Oct. 8, 2024

News

ZBIO INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
ZBIO
Published: May 16, 2025 by: GlobeNewsWire
Sentiment: Neutral

SAN DIEGO, May 16, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma's registration statement issued in connection with Zenas BioPharma's initial public offering (the “IPO”) held on or around September 13, 2024, and were damaged thereby, have until June 16, 2025 to seek appointment as lead plaintiff of the Zenas BioPharma class action lawsuit. Captioned Buathongsri v. Zenas BioPharma, Inc., No. 25-cv-10988 (D. Mass.), the Zenas BioPharma class action lawsuit charges Zenas BioPharma as well as certain of Zenas BioPharma's …

Read More
image for news ZBIO INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
Investors in Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO
ZBIO
Published: May 16, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , May 16, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud.

Read More
image for news Investors in Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO
Levi & Korsinsky Notifies Zenas BioPharma, Inc. (ZBIO) Shareholders of Class Action Lawsuit and June 16, 2025 Deadline
ZBIO
Published: May 15, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 15, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=148731&wire=1&utm_campaign=15 or contact Joseph E. Levi, Esq.

Read More
image for news Levi & Korsinsky Notifies Zenas BioPharma, Inc. (ZBIO) Shareholders of Class Action Lawsuit and June 16, 2025 Deadline
Reminder from Cohen Milstein: Zenas BioPharma (ZBIO) Lead Plaintiff Deadline in ZBIO Stock Drop Suit Approaching
ZBIO
Published: May 15, 2025 by: GlobeNewsWire
Sentiment: Neutral

Zenas BioPharma investors are encouraged to call Cohen Milstein's Molly Bowen, Esq. about becoming a lead plaintiff in the ZBIO stock drop class action.

Read More
image for news Reminder from Cohen Milstein: Zenas BioPharma (ZBIO) Lead Plaintiff Deadline in ZBIO Stock Drop Suit Approaching
The Gross Law Firm Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 16, 2025 – ZBIO
ZBIO
Published: May 15, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO).

Read More
image for news The Gross Law Firm Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 16, 2025 – ZBIO
Contact Levi & Korsinsky by June 16, 2025 to Join Class Action Against Zenas BioPharma, Inc. (ZBIO)
ZBIO
Published: May 14, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 14, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=148542&wire=1&utm_campaign=10 or contact Joseph E. Levi, Esq.

Read More
image for news Contact Levi & Korsinsky by June 16, 2025 to Join Class Action Against Zenas BioPharma, Inc. (ZBIO)
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ZBIO
ZBIO
Published: May 14, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / May 14, 2025 / WHY: New York, N.Y., May 14, 2025.

Read More
image for news ROSEN, SKILLED INVESTOR COUNSEL, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ZBIO
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
ZBIO
Published: May 14, 2025 by: GlobeNewsWire
Sentiment: Neutral

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Zenas To Contact Him Directly To Discuss Their Options

Read More
image for news INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
Securities Class Action Lawsuit Filed Against Zenas BioPharma, Inc. (ZBIO) - Levi & Korsinsky Represents Shareholders
ZBIO
Published: May 14, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 14, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=148477&wire=1&utm_campaign=13 or contact Joseph E. Levi, Esq.

Read More
image for news Securities Class Action Lawsuit Filed Against Zenas BioPharma, Inc. (ZBIO) - Levi & Korsinsky Represents Shareholders
Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights – ZBIO
ZBIO
Published: May 13, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit.

Read More
image for news Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights – ZBIO
Class Action Filed Against Zenas BioPharma, Inc. (ZBIO) - June 16, 2025 Deadline to Join - Contact Levi & Korsinsky
ZBIO
Published: May 13, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 13, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=148259&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Class Action Filed Against Zenas BioPharma, Inc. (ZBIO) - June 16, 2025 Deadline to Join - Contact Levi & Korsinsky
Class Action Filed Against Zenas BioPharma, Inc. (ZBIO) - June 16, 2025 Deadline to Join - Contact Levi & Korsinsky
ZBIO
Published: May 13, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 13, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=148259&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Class Action Filed Against Zenas BioPharma, Inc. (ZBIO) - June 16, 2025 Deadline to Join - Contact Levi & Korsinsky
Levi & Korsinsky Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of June 16, 2025 - ZBIO
ZBIO
Published: May 12, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=148137&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Levi & Korsinsky Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of June 16, 2025 - ZBIO
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
ZBIO
Published: May 12, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , May 12, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
Zenas BioPharma, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before June 16, 2025 to Discuss Your Rights – ZBIO
ZBIO
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO).

Read More
image for news Zenas BioPharma, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before June 16, 2025 to Discuss Your Rights – ZBIO
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Zenas BioPharma, Inc. (ZBIO) Shareholders
ZBIO
Published: May 12, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=148079&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Zenas BioPharma, Inc. (ZBIO) Shareholders
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
ZBIO
Published: May 12, 2025 by: PRNewsWire
Sentiment: Neutral

LOS ANGELES , May 12, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zenas BioPharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's Offering Documents issued in connection with its initial public offering ("IPO") conducted on September 13, 2024, are encouraged to contact the firm before June 16, 2025.

Read More
image for news ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO
ZBIO
Published: May 12, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=147998&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO
Lost Money on Zenas BioPharma, Inc.(ZBIO)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
ZBIO
Published: May 12, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , May 12, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO). Shareholders who purchased shares of ZBIO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Read More
image for news Lost Money on Zenas BioPharma, Inc.(ZBIO)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
ZBIO
Published: May 11, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 11, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=147979&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Zenas BioPharma, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO
ZBIO
Published: May 11, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 11, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=147967&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Zenas BioPharma, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ZBIO
ZBIO
Published: May 11, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / May 11, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc.(NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Zenas BioPharma's September 2024 initial public offering ("IPO" or the "Offering"), of the important June 16, 2025 lead plaintiff deadline in the securities class action first filed by the firm. SO WHAT: If you purchased Zenas BioPharma securities you may be entitled to compensation without payment of any out of pocket …

Read More
image for news ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ZBIO
Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO
ZBIO
Published: May 09, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 9, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=147697&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO
Levi & Korsinsky Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 16, 2025 - ZBIO
ZBIO
Published: May 09, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 9, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=147680&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Levi & Korsinsky Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 16, 2025 - ZBIO
ZBIO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Zenas BioPharma, Inc. to Contact the Firm Today!
ZBIO
Published: May 09, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 9, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Zenas BioPharma, Inc. ("Zenas BioPharma" or "the Company") (NASDAQ:ZBIO) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Zenas BioPharma securities pursuant to the registration statement and prospectus issued in connection with the Company's September 13, 2024 initial public offering ("IPO").

Read More
image for news ZBIO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Zenas BioPharma, Inc. to Contact the Firm Today!
Levi & Korsinsky Notifies Shareholders of Zenas BioPharma, Inc.(ZBIO) of a Class Action Lawsuit and an Upcoming Deadline
ZBIO
Published: May 09, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , May 9, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud.

Read More
image for news Levi & Korsinsky Notifies Shareholders of Zenas BioPharma, Inc.(ZBIO) of a Class Action Lawsuit and an Upcoming Deadline
June 16, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ZBIO
ZBIO
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 8, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=147657&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news June 16, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ZBIO
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ZBIO
ZBIO
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / WHY: New York, N.Y., May 8, 2025.

Read More
image for news ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ZBIO
Lost Money on Zenas BioPharma, Inc.(ZBIO)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
ZBIO
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit.

Read More
image for news Lost Money on Zenas BioPharma, Inc.(ZBIO)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
Zenas BioPharma, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO
ZBIO
Published: May 08, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / May 8, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=147521&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Zenas BioPharma, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO

About Zenas BioPharma, Inc. (ZBIO)

  • IPO Date 2024-09-13
  • Website https://zenasbio.com
  • Industry Biotechnology
  • CEO Leon Oliver Moulder Jr.,
  • Employees 130

Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.